Why the study?
Does disopyramide induce ventricular tachycardia in patients with ischemic cardiomyopathy and congestive heart failure?
Does disopyramide induce ventricular tachycardia in patients with ischemic cardiomyopathy and congestive heart failure?
Disopyramide can induce ventricular tachycardia and prolong QRS and QT intervals in patients with congestive heart failure, necessitating cautious use in this population.
May warrant caution with disopyramide in heart failure; single case leaves open causality and need for prospective data.
A patient with ischemic cardiomyopathy and congestive heart failure was treated with disopyramide phosphate for ventricular arrhythmias. The development of ventricular tachycardia was associated with elevated plasma disopyramide levels and prolongation of the QRS and QT intervals, suggesting a disopyramide-induced depression of ventricular conduction and a prolongation of recovery. Thus, in patients with congestive heart failure, as well as in patients with renal and/or hepatic dysfunction, special care must be exercised with respect to the use of disopyramide.
No takes yet. Share an insight, caveat, or question.
Ka Lo (1980) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: